Visual pathway glioma: An erratic tumour with therapeutic dilemmas

A. Shuper*, G. Horev, L. Kornreich, S. Michowiz, R. Weitz, R. Zaizov, I. J. Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective - Our experience in children with visual pathway glioma (VPG) was reviewed to delineate its clinical characteristics. Design - The charts and imaging studies of 21 children with VPG who were followed up in our centre during the last 12 years were reviewed and summarised. Results - VPG accounted for 13.1% of all brain tumours treated during this period. Sixty two per cent of the children with VPG had neurofibromatosis type 1 (NF-1). Among these, more than 60% were detected as part of routine work-up. In some cases decreasing visual function preceded the appearance of the VPG on imaging studies. Tumour growth rate was markedly unpredictable. All treatment modalities employed led to tumour shrinkage and stabilisation for a variable period, but none was successful in totally eradicating the tumour. Complications were less severe after chemotherapy compared with radiotherapy. Three children died, none with NF-1, with a globular hypothalamic/chiasmatic tumour and accompanying electrolyte abnormalities. Conclusions - NF-1 is a favourable prognostic marker for VPG. Whenever possible a period of observation is necessary before treatment is initiated, during which time tumour size and visual function should be closely followed up; an untoward change in either of these is an indication for the start of treatment, preferably chemotherapy first. The combination of a globular hypothalamic/chiasmatic glioma and electrolyte abnormalities in a child without NF-1 are related to a poor prognosis.

Original languageEnglish
Pages (from-to)259-263
Number of pages5
JournalArchives of Disease in Childhood
Issue number3
StatePublished - 1997


  • chemotherapy
  • neurofibromatosis
  • optic glioma
  • radiation therapy


Dive into the research topics of 'Visual pathway glioma: An erratic tumour with therapeutic dilemmas'. Together they form a unique fingerprint.

Cite this